Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: Individual patient data meta-analysis

BMJ (Online)

Volumn 353, Issue , 2016, Pages

  Kotecha, Dipak ^a,b   Manzano, Luis ^c   Krum, Henry ^b   Rosano, Giuseppe ^d,e   Holmes, Jane ^f   Altman, Douglas G ^f   Collins, Peter D ^g   Packer, Milton ^h   Wikstrand, John ⁱ   Coats, Andrew J S ^b,j   Cleland, John G F ^g   Kirchhof, Paulus ^a   Von Lueder, Thomas G ^k   Rigby, Alan S ^l   Andersson, Bert ⁱ   Lip, Gregory Y H ^a   Van Veldhuisen, Dirk J ^m   Shibata, Marcelo C ⁿ   Wedel, Hans ^o   Böhm, Michael ^p   Flather, Marcus D ^q   more..

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

^j UNIVERSITY OF WARWICK   (United Kingdom)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l CASTLE HILL HOSPITAL   (United Kingdom)

^m UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁿ UNIVERSITY OF ALBERTA   (Canada)

^o NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^p SAARLAND UNIVERSITY   (Germany)

^q UNIVERSITY OF EAST ANGLIA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGE DISTRIBUTION; ARTICLE; BRADYCARDIA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; KIDNEY DISEASE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX; SINUS RHYTHM; ADULT; AGE; AGED; FEMALE; HEART STROKE VOLUME; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SEX DIFFERENCE; TREATMENT OUTCOME; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84964599865     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i1855     Document Type: Article

References (53)

1. Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 2009;30:478-86. doi:10.1093/eurheartj/ehn539.
2. Baumhakel M, Muller U, Bohm M. Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail 2009;11:299-303. doi:10.1093/eurjhf/hfn041.
3. Mehta PA, Cowie MR. Gender and heart failure: a population perspective. Heart 2006;92(Suppl 3):iii14-8. doi:10.1136/hrt.2005.070342.
4. Ali Raza J, Movahed A. Use of cardiovascular medications in the elderly. Int J Cardiol 2002;85:203-15. doi: 10.1016/S0167-5273 (02) 00193-6.
5. Hsich EM, Pina IL. Heart failure in women: a need for prospective data. J Am Coll Cardiol 2009;54:491-8. doi:10.1016/j.jacc.2009.02.066.
6. Dobre D, Haaijer-Ruskamp FM, Voors AA, van Veldhuisen DJ. beta-Adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerability. Drugs Aging 2007;24:1031-44. doi:10.2165/00002512-200724120-00006.
7. Deedwania PC, Gottlieb S, Ghali JK, Waagstein F, Wikstrand JC. MERIT-HF Study Group. Efficacy, safety and tolerability of betaadrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004;25:1300-9. doi:10.1016/j. ehj.2004.05.022.
8. Flather MD, Shibata MC, Coats AJ, et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25. doi:10.1093/eurheartj/ehi115.
9. Kotecha D, Manzano L, Altman DG, et al. Beta-Blockers in Heart Failure Collaborative Group. Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design. Syst Rev 2013;2:7. doi:10.1186/2046-4053-2-7.
10. Kotecha D, Manzano L, Krum H, Altman DG, Holmes J, Flather M. The Beta-Blockers in Heart Failure Collaborative Group. Individual patient data meta-analysis. PROSPERO register. 2014: http://www.crd.york. ac.uk/PROSPERO/display-record.asp?ID=CRD42014010012.
11. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002;25:76-97. doi:10.1177/0163278702025001006.
12. Kotecha D, Holmes J, Krum H, et al. Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235-43. doi:10.1016/S0140-6736 (14) 61373-8.
13. Stewart LA, Clarke M, Rovers M, et al. PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA 2015;313:1657-65. doi:10.1001/jama.2015.3656.
14. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80. doi:10.1016/S0140-6736 (97) 80008-6.
15. Beta-Blocker Evaluation of Survival Trial Investigators Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67. doi:10.1056/NEJM200105313442202.
16. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90. doi:10.1016/S0140-6736 (00) 04560-8.
17. Cleland JG, Pennell DJ, Ray SG, et al. Carvedilol hibernating reversible ischaemia trial: marker of success investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003;362:14-21. doi:10.1016/S0140-6736 (03) 13801-9.
18. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994;90:1765-73. doi:10.1161/01. CIR.90.4.1765.
19. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13. doi:10.1016/S0140-6736 (98) 11181-9.
20. Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8. doi:10.1056/NEJM200105313442201.
21. Waagstein F, Bristow MR, Swedberg K, et al. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6. doi:10.1016/0140-6736 (93) 92930-R.
22. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7. doi:10.1016/S0140-6736 (99) 04440-2.
23. Hjalmarson A, Goldstein S, Fagerberg B, et al. MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295-302. doi:10.1001/jama.283.10.1295.
24. Packer M, Bristow MR, Cohn JN, et al. U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55. doi:10.1056/NEJM199605233342101.
25. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 510. Cochrane Collaboration, 2011.
26. Tudur Smith C, Williamson PR. A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes. Clin Trials 2007;4:621-30. doi:10.1177/1740774507085276.
27. Smith CT, Williamson PR, Marson AG. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med 2005;24:1307-19. doi:10.1002/sim.2050.
28. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239-41. doi:10.1093/biomet/69.1.239.
29. Koopman L, van der Heijden GJMG, Hoes AW, Grobbee DE, Rovers MM. Empirical comparison of subgroup effects in conventional and individual patient data meta-analyses. Int J Technol Assess Health Care 2008;24:358-61. doi:10.1017/S0266462308080471.
30. Sauerbrei W, Royston P. Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. JR Stat Soc 1999;162:71-94. doi:10.1111/1467-985X.00122.
31. Royston P, Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 2004;23:2509-25. doi:10.1002/sim.1815.
32. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847. doi:10.1093/eurheartj/ehs104.
33. Yancy CW, Jessup M, Bozkurt B, et al. WRITING COMMITTEE MEMBERS American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240-327. doi:10.1161/CIR.0b013e31829e8807.
34. Follath F. Beta-blockade today: the gap between evidence and practice. Eur Heart J Suppl 2006;8(suppl C):C28-34 doi:10.1093/eurheartj/sul011.
35. Shah SM, Carey IM, DeWilde S, Richards N, Cook DG. Trends and inequities in beta-blocker prescribing for heart failure. Br J Gen Pract 2008;58:862-9. doi:10.3399/bjgp08X376195.
36. Sinha S, Goldstein M, Penrod J, et al. Brief report: beta-blocker use among veterans with systolic heart failure. J Gen Intern Med 2006;21:1306-9. doi:10.1111/j.1525-1497.2006.00601.x.
37. Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 2014;64:2281-93. doi:10.1016/j.jacc.2014.08.036.
38. Alehagen U, Benson L, Edner M, Dahlström U, Lund LH. Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry. Circ Heart Fail 2015;8:252-60. doi:10.1161/CIRCHEARTFAILURE.114.001730.
39. Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users' guide to the medical literature. JAMA 2014;311:405-11. doi:10.1001/jama.2013.285063.
40. Stromberg A, Martensson J. Gender differences in patients with heart failure. Eur J Cardiovasc Nurs 2003;2:7-18.
41. Martínez-Sellés M, Doughty RN, Poppe K, et al. Meta-Analysis Global Group In Chronic Heart Failure (MAGGIC). Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. Eur J Heart Fail 2012;14:473-9. doi:10.1093/eurjhf/hfs026.
42. Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies-CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 2002;143:301-7. doi:10.1067/mhj.2002.120768.
43. Ghali JK, Piña IL, Gottlieb SS, Deedwania PC, Wikstrand JC. MERIT-HF Study Group. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002;105:1585-91. doi:10.1161/01. CIR.0000012546.20194.33.
44. Ghali JK, Krause-Steinrauf HJ, Adams KF, et al. Gender differences in advanced heart failure: insights from the BEST study. J Am Coll Cardiol 2003;42:2128-34. doi:10.1016/j.jacc.2003.05.012.
45. Sheppard R, Behlouli H, Richard H, Pilote L. Effect of gender on treatment, resource utilization, and outcomes in congestive heart failure in Quebec, Canada. Am J Cardiol 2005;95:955-9. doi:10.1016/j. amjcard.2004.12.033.
46. McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. doi:10.1056/NEJMoa1409077.
47. Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 2013;168:3572-9. doi:10.1016/j.ijcard.2013.05.068.
48. Ko DT, Hebert PR, Coffey CS, et al. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med 2004;164:1389-94. doi:10.1001/archinte.164.13.1389.
49. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-7. doi:10.1001/jama.288.3.351.
50. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 2016;203:660-6. doi:10.1016/j.ijcard.2015.10.220.
51. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J 2015;36:3250-7.
52. Voigt A, Shalaby A, Adelstein E, Saba S. Beta-blocker utilization and outcomes in patients receiving cardiac resynchronization therapy. Clin Cardiol 2010;33:E1-5. doi:10.1002/clc.20500.
53. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. doi:10.1056/NEJMoa030207.